Onco-Hematology Molecular Testing Market Report: Trends, Forecast and Competitive Analysis to 2031
상품코드:1871569
리서치사:Lucintel
발행일:2025년 11월
페이지 정보:영문 150 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계 종양혈액 분자 검사 시장의 미래는 국가 표준 실험실/전문 실험실, 대학 병원, 지역 병원 시장에서의 기회를 배경으로 유망한 전망을 보여주고 있습니다. 세계 종양혈액 분자 검사 시장은 2025년부터 2031년까지 CAGR 6.5%로 성장할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 맞춤형 의료 및 표적치료에 대한 수요 증가와 진단 정확도를 향상시킬 수 있는 분자 검사 기술의 발전입니다.
Lucintel의 예측에 따르면, 유형별로는 예측 기간 동안 국가 표준 실험실이 가장 큰 부문을 유지할 것으로 예상됩니다.
용도별로는 국가 표준 검사실/전문검사실이 더 높은 성장률을 보일 것으로 예상됩니다.
지역별로는 아시아태평양(APAC)이 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다.
종양혈액 분자 검사 시장의 새로운 동향
종양혈액 분자 검사 세계 시장은 진단 및 치료 전략의 미래를 형성하는 몇 가지 새로운 트렌드에 의해 주도되고 있습니다. 이러한 추세는 기술, 정밀의료, 맞춤형 의료의 진보를 잘 보여주고 있습니다.
차세대 염기서열분석(NGS) 기술의 발전 : NGS 기술은 분자 검사에 혁명을 가져왔으며, 혈액 악성종양에서 광범위한 유전자 변이를 검출할 수 있게 되었습니다. 이 기술을 통해 종합적인 유전자 프로파일링이 가능해져 예후, 질병 진행, 치료 반응에 대한 지식을 얻을 수 있어 혈액암 환자들에게 보다 맞춤화된 치료를 제공할 수 있게 되었습니다.
액체 생검 도입 : 액체 생검은 기존의 생검법을 대체할 수 있는 비침습적 대안으로 주목받고 있습니다. 혈액 샘플을 통해 유전자 돌연변이 및 변화를 감지할 수 있어 질병의 진행 및 치료 효과의 모니터링이 용이해집니다. 특히 백혈병 등 혈액암 관리에서 기존 생검법이 어려운 경우에도 유용하게 사용할 수 있습니다.
표적 치료의 통합 : 분자 검사는 표적 치료의 바이오마커를 식별하고 치료 효과를 높이는 데 중요한 역할을 합니다. 특정 유전자 변이에 맞춘 표적 치료제는 부작용을 최소화하고, 특히 림프종, 골수종 등 혈액암 환자의 치료 성적을 개선하기 위해 보급이 확대되고 있습니다.
진단의 AI와 머신러닝 : 분자 검사에 인공지능(AI)과 머신러닝을 통합하여 진단의 정확도를 높이고 있습니다. AI는 유전자 데이터의 신속한 분석에 활용되어 혈액악성종양의 조기 발견과 개인별 맞춤 치료 계획 수립을 가능하게 하고, 궁극적으로 임상적 판단의 질적 향상에 기여하고 있습니다.
검사 접근성 확대 : 신흥 시장에서의 의료 접근성 향상으로 종양혈액 분자 검사의 보급이 확대되고 있습니다. 정부, 의료진, 진단기업이 협력하여 이러한 첨단 검사 기술을 보다 저렴한 가격에 이용할 수 있도록함으로써 의료 자원이 부족한 지역에서 조기 진단 및 치료 성과를 향상시키고자 노력하고 있습니다.
전 세계 종양혈액 분자 검사 시장의 새로운 트렌드는 진단 방법, 치료 접근법, 환자 치료 방식을 변화시키고 있습니다. 차세대 시퀀싱과 액체 생검의 등장부터 AI와 표적 치료의 통합에 이르기까지, 이러한 추세는 개인화된 비침습적 진단을 더욱 접근하기 쉽고 정밀하게 만들어주고 있습니다. 이러한 기술의 보급 확대는 환자 예후 개선과 종양혈액학 검사 분야의 큰 발전을 촉진할 것으로 예상됩니다.
종양혈액 분자 검사 시장의 최근 동향
최근 세계 종양혈액 분자 검사 시장의 발전은 진단 정확도와 환자 예후를 개선하기 위한 지속적인 노력을 반영하고 있습니다. 이러한 발전은 기술 혁신과 맞춤형 의료에 대한 수요 증가에 의해 촉진되고 있습니다.
분자진단 도구의 FDA 승인 : 미국에서는 혈액암에 대한 여러 분자진단 도구가 FDA 승인을 받아 조기 발견 및 치료 모니터링의 정확성을 향상시키고 있습니다. 이번 승인은 혈액암 관리에서 분자 검사의 중요성을 입증하는 동시에 임상 현장에서 보다 진보된 기술을 도입할 수 있는 길을 열어주었습니다.
혈액암 검사에서 액체 생검의 채택 : 액체 생검의 보급은 혈액암의 진단 및 경과 관찰 방법을 변화시키고 있습니다. 액체 생검을 통해 임상의는 혈액 샘플을 사용하여 돌연변이 및 질병 진행을 추적할 수 있으며, 특히 백혈병 및 림프종 환자에게 덜 침습적이고 편리한 검사 방법을 제공합니다.
차세대 시퀀싱(NGS) 플랫폼의 기술적 진보 : 보다 정확하고 비용 효율적인 NGS 플랫폼의 개발로 분자 검사는 전 세계적으로 쉽게 이용할 수 있게 되었습니다. 희귀 돌연변이 및 유전적 변화를 식별하는 능력이 향상된 NGS는 종합적인 유전체 데이터를 제공함으로써 정밀의료를 실현하고 혈액암 환자의 치료 결과를 향상시키고 있습니다.
검사 접근성 향상을 위한 협력 : 의료 제공자, 진단 기업, 정부 기관 간의 협력 강화로 선진국과 개발도상국 모두에서 분자검사의 접근성이 향상되고 있습니다. 이러한 파트너십은 분자 검사 기술을 보다 많은 환자들에게 보다 합리적인 가격으로 제공하는 데 초점을 맞추고 있습니다.
분자검사의 데이터 분석에 AI 통합 : 복잡한 유전자 데이터를 보다 효율적으로 분석하기 위해 인공지능이 분자검사 플랫폼에 통합되고 있습니다. AI는 데이터 해석의 속도와 정확성을 향상시킴으로써 임상의가 치료 계획과 질병 모니터링에 대해 보다 현명한 판단을 내릴 수 있도록 돕고 있습니다.
이러한 주요 발전은 전 세계 종양혈액 분자 검사 시장에 큰 영향을 미치고 있습니다. FDA 승인과 액체 생검의 성장, 차세대 시퀀싱(NGS) 기술의 발전, AI 통합에 이르기까지 이러한 혁신은 진단 능력을 향상시키고, 보다 개인화된 치료를 가능하게 하며, 분자 검사의 적용 범위를 확장하고 있습니다. 이러한 것들이 결합되어 보다 정밀하고 접근하기 쉬운 종양혈액학 의료의 미래를 제시하고 있습니다.
목차
제1장 주요 요약
제2장 시장 개요
배경과 분류
공급망
제3장 시장 동향과 예측 분석
업계 성장 촉진요인과 과제
PESTLE 분석
특허 분석
규제 환경
제4장 세계의 종양혈액 분자 검사 시장 : 종류별
개요
매력 분석 : 종류별
qPCR : 동향과 예측(2019-2031년)
dPCR : 동향과 예측(2019-2031년)
차세대 시퀀싱 : 동향과 예측(2019-2031년)
기타 : 동향과 예측(2019-2031년)
제5장 세계의 종양혈액 분자 검사 시장 : 용도별
개요
매력 분석 : 용도별
국가 표준 검사실/전문 검사실 : 동향과 예측(2019-2031년)
대학 병원 : 동향과 예측(2019-2031년)
커뮤니티 병원 : 동향과 예측(2019-2031년)
제6장 지역 분석
개요
세계의 종양혈액 분자 검사 시장 : 지역별
제7장 북미의 종양혈액 분자 검사 시장
개요
북미의 종양혈액 분자 검사 시장 : 종류별
북미의 종양혈액 분자 검사 시장 : 용도별
미국의 종양혈액 분자 검사 시장
멕시코의 종양혈액 분자 검사 시장
캐나다의 종양혈액 분자 검사 시장
제8장 유럽의 종양혈액 분자 검사 시장
개요
유럽의 종양혈액 분자 검사 시장 : 종류별
유럽의 종양혈액 분자 검사 시장 : 용도별
독일의 종양혈액 분자 검사 시장
프랑스의 종양혈액 분자 검사 시장
스페인의 종양혈액 분자 검사 시장
이탈리아의 종양혈액 분자 검사 시장
영국의 종양혈액 분자 검사 시장
제9장 아시아태평양의 종양혈액 분자 검사 시장
개요
아시아태평양의 종양혈액 분자 검사 시장 : 종류별
아시아태평양의 종양혈액 분자 검사 시장 : 용도별
일본의 종양혈액 분자 검사 시장
인도의 종양혈액 분자 검사 시장
중국의 종양혈액 분자 검사 시장
한국의 종양혈액 분자 검사 시장
인도네시아의 종양혈액 분자 검사 시장
제10장 기타 지역(ROW)의 종양혈액 분자 검사 시장
개요
ROW의 종양혈액 분자 검사 시장 : 종류별
ROW의 종양혈액 분자 검사 시장 : 용도별
중동의 종양혈액 분자 검사 시장
남미의 종양혈액 분자 검사 시장
아프리카의 종양혈액 분자 검사 시장
제11장 경쟁 분석
제품 포트폴리오 분석
운영 통합
Porter's Five Forces 분석
경쟁 기업 간의 경쟁 관계
구매자의 협상력
공급업체의 협상력
대체품의 위협
신규 참여업체의 위협
시장 점유율 분석
제12장 기회와 전략 분석
밸류체인 분석
성장 기회 분석
성장 기회 : 종류별
성장 기회 : 용도별
세계의 종양혈액 분자 검사 시장 최신 동향
전략 분석
신제품 개발
인증·라이선싱
기업 인수합병(M&A) , 계약, 제휴, 합작투자
제13장 밸류체인 전반에 걸친 주요 기업 개요
경쟁 분석
Asuragen
Bio-Rad Laboratories
Illumina
QIAGEN
Cepheid
제14장 부록
그림목차
표목차
분석 방법
면책사항
저작권
약어와 기술 단위
Lucintel 소개
문의
KSM
영문 목차
영문목차
The future of the global onco-hematology molecular testing market looks promising with opportunities in the national reference lab / specialty lab, university hospital, and community hospital markets. The global onco-hematology molecular testing market is expected to grow with a CAGR of 6.5% from 2025 to 2031. The major drivers for this market are the growing demand for personalized medicine and targeted therapies and the advancements in molecular testing technologies enabling better diagnostic accuracy.
Lucintel forecasts that, within the type category, national reference lab will remain the largest segment over the forecast period.
Within the application category, national reference lab/ specialty labs is expected to witness the higher growth.
In terms of region, APAC is expected to witness the highest growth over the forecast period.
Emerging Trends in the Onco-Hematology Molecular Testing Market
The global market for onco-hematology molecular testing is driven by several emerging trends that are shaping the future of diagnostics and treatment strategies. These trends highlight advancements in technology, precision medicine, and personalized care.
Next-Generation Sequencing (NGS) Advancements: NGS technology is revolutionizing molecular testing, enabling the detection of a wide range of genetic mutations in hematologic malignancies. This technology allows for comprehensive genetic profiling, offering insights into prognosis, disease progression, and treatment response, leading to more personalized care for patients with blood cancers.
Liquid Biopsy Adoption: Liquid biopsy is gaining traction as a non-invasive alternative to traditional biopsy methods. It enables the detection of genetic mutations and alterations through blood samples, making it easier to monitor disease progression and treatment efficacy. Liquid biopsy is particularly valuable for managing hematologic cancers like leukemia, where traditional biopsy methods may be challenging.
Targeted Therapy Integration: Molecular testing plays a critical role in identifying biomarkers for targeted therapies, enhancing treatment efficacy. Targeted treatments tailored to specific genetic mutations are gaining popularity, as they help minimize side effects and improve patient outcomes, particularly for patients with hematologic cancers like lymphoma and myeloma.
AI and Machine Learning in Diagnostics: The integration of artificial intelligence (AI) and machine learning in molecular testing is enhancing diagnostic accuracy. AI is being used to analyze genetic data quickly, enabling earlier detection of hematologic malignancies and the identification of personalized treatment plans, ultimately improving clinical decision-making.
Expansion of Testing Access: Increasing healthcare access in emerging markets is leading to the wider adoption of onco-hematology molecular testing. Governments, healthcare providers, and diagnostic companies are working together to make these advanced testing technologies more affordable and accessible, ultimately improving early diagnosis and treatment outcomes in underserved regions.
Emerging trends in the global onco-hematology molecular testing market are reshaping diagnostics, treatment approaches, and patient care. From the rise of next-generation sequencing and liquid biopsies to the integration of AI and targeted therapies, these trends are making personalized, non-invasive diagnostics more accessible and precise. The growing adoption of these technologies is set to improve patient outcomes and drive significant advancements in onco-hematology testing.
Recent Developments in the Onco-Hematology Molecular Testing Market
Recent advancements in the global onco-hematology molecular testing market reflect ongoing efforts to improve diagnostic accuracy and patient outcomes. These developments are driven by technological innovations and increased demand for personalized medicine.
FDA Approvals for Molecular Diagnostic Tools: In the U.S., several molecular diagnostic tools for hematologic cancers have received FDA approval, enabling better early detection and treatment monitoring. These approvals validate the importance of molecular testing in managing blood cancers, and they open the door for more advanced technologies in clinical practice.
Adoption of Liquid Biopsy in Hematologic Cancer Testing: The widespread use of liquid biopsy is transforming how hematologic cancers are diagnosed and monitored. Liquid biopsy allows clinicians to track mutations and disease progression using blood samples, which is particularly useful for patients with leukemia or lymphoma, offering a less invasive and more convenient testing method.
Technological Advancements in NGS Platforms: The development of more accurate and cost-effective NGS platforms is making molecular testing more accessible globally. With enhanced capabilities to identify rare mutations and genetic changes, NGS is enabling precision medicine and improving treatment outcomes for patients with hematologic cancers by providing comprehensive genomic data.
Collaborations to Improve Testing Access: Increased collaboration between healthcare providers, diagnostic companies, and government agencies is improving the accessibility of molecular testing in both developed and developing countries. These partnerships are focusing on making molecular testing technologies affordable and available to a wider patient population.
Integration of AI in Data Analysis for Molecular Testing: Artificial intelligence is being integrated into molecular testing platforms to analyze complex genetic data more efficiently. By improving the speed and accuracy of data interpretation, AI is helping clinicians make more informed decisions about treatment plans and disease monitoring.
These key developments are having a profound impact on the global onco-hematology molecular testing market. From FDA approvals and the growth of liquid biopsy to NGS advancements and AI integration, these innovations are improving diagnostic capabilities, enabling more personalized treatment, and expanding the reach of molecular testing. Together, they signal a future of more precise and accessible onco-hematology care.
Strategic Growth Opportunities in the Onco-Hematology Molecular Testing Market
The global onco-hematology molecular testing market is filled with growth opportunities in various applications. These opportunities reflect the continued demand for advanced diagnostic tools and treatments tailored to hematologic malignancies.
NGS for Precision Diagnosis: Next-generation sequencing (NGS) is becoming a critical tool for diagnosing hematologic cancers. By providing comprehensive insights into genetic mutations, NGS enables more precise diagnoses, better monitoring of disease progression, and personalized treatment plans, offering significant growth potential in both developed and emerging markets.
Liquid Biopsy for Non-Invasive Testing: The adoption of liquid biopsy technology is a key growth opportunity in onco-hematology testing. Liquid biopsy is gaining acceptance as a non-invasive, accurate method for detecting genetic mutations and monitoring treatment responses, making it a valuable tool in hematologic cancer care.
AI-Driven Diagnostic Tools: The integration of artificial intelligence (AI) into molecular testing platforms presents a growth opportunity by enhancing diagnostic accuracy and speed. AI algorithms can analyze vast amounts of genetic data more effectively, leading to earlier detection of hematologic malignancies and better-informed treatment decisions.
Expansion of Testing Access: There is a significant growth opportunity in expanding access to molecular testing in underserved regions. Public-private partnerships, alongside government support, can help make these advanced diagnostic tools affordable and accessible in developing countries, improving early detection and treatment outcomes in blood cancer care.
Targeted Therapies Based on Molecular Profiling: Molecular testing is crucial for identifying biomarkers that guide targeted therapies. The ability to offer personalized treatment for hematologic cancers such as leukemia and lymphoma creates a growth opportunity for molecular testing companies, especially those focused on developing and integrating new therapies.
The strategic growth opportunities in the onco-hematology molecular testing market highlight the industry's potential to improve diagnostic accuracy, patient outcomes, and treatment options. From NGS and liquid biopsy advancements to AI integration and targeted therapies, these opportunities will drive significant market growth and better patient care in the years to come.
Onco-Hematology Molecular Testing Market Driver and Challenges
The global onco-hematology molecular testing market is influenced by several drivers and challenges, shaping its growth trajectory and adoption of advanced diagnostic technologies.
The factors responsible for driving the onco-hematology molecular testing market include:
1. Technological Advancements in Diagnostics: The development of next-generation sequencing (NGS), liquid biopsies, and AI has revolutionized molecular testing. These technologies allow for more accurate, comprehensive, and less invasive testing methods, driving market growth by improving diagnosis and personalized treatment for hematologic cancers.
2. Rising Demand for Personalized Medicine: There is a growing demand for personalized medicine in oncology and hematology, with molecular testing playing a critical role in identifying genetic mutations and tailoring treatments. This demand drives the adoption of molecular diagnostics, as patients and healthcare providers seek more effective and targeted treatment options.
3. Government Support for Healthcare Innovations: Governments around the world are investing in healthcare innovations, including molecular diagnostics. Regulatory frameworks, such as those in the U.S. and China, promote the approval and adoption of advanced molecular testing technologies, providing a favorable environment for market growth.
4. Increasing Awareness of Hematologic Cancer: As awareness of hematologic cancers like leukemia and lymphoma increases, more patients are seeking early diagnostic tests. This awareness is driving the demand for molecular testing, particularly in regions where healthcare infrastructure is improving.
5. Growing Healthcare Expenditure: Higher healthcare spending globally, especially in emerging markets, is making advanced diagnostic tools more accessible. As healthcare budgets increase, more funds are allocated to cancer research and diagnostics, boosting the molecular testing market.
Challenges in the onco-hematology molecular testing market are:
1. High Cost of Molecular Testing: One of the major challenges is the high cost of advanced molecular testing technologies, which can limit accessibility for patients, particularly in low- and middle-income countries. Despite advances in technology, affordability remains a significant barrier.
2. Regulatory and Reimbursement Issues: Regulatory hurdles and lack of consistent reimbursement policies in different countries can slow the adoption of molecular testing. Variations in regulatory approval timelines and reimbursement criteria hinder the widespread use of new diagnostic tools.
3. Limited Healthcare Infrastructure in Developing Regions: Although demand is rising in emerging markets, limited healthcare infrastructure and a lack of trained professionals pose challenges to the adoption of advanced molecular testing technologies in these regions. Overcoming these barriers is key to global market growth.
The drivers of technological innovation, government support, and increasing demand for personalized care are helping shape the growth of the onco-hematology molecular testing market. However, challenges related to cost, regulatory issues, and healthcare infrastructure limitations must be addressed to fully realize the potential of these innovations. Addressing these challenges will be essential for expanding access to cutting-edge diagnostic tools worldwide.
List of Onco-Hematology Molecular Testing Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies onco-hematology molecular testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the onco-hematology molecular testing companies profiled in this report include-
Asuragen
Bio-Rad Laboratories
Illumina
QIAGEN
Cepheid
Onco-Hematology Molecular Testing Market by Segment
The study includes a forecast for the global onco-hematology molecular testing market by type, application, and region.
Onco-Hematology Molecular Testing Market by Type [Value from 2019 to 2031]:
qPCR
dPCR
Next-Generation Sequencing
Others
Onco-Hematology Molecular Testing Market by Application [Value from 2019 to 2031]:
National Reference Lab / Specialty Lab
University Hospital
Community Hospital
Onco-Hematology Molecular Testing Market by Region [Value from 2019 to 2031]:
North America
Europe
Asia Pacific
The Rest of the World
Country Wise Outlook for the Onco-Hematology Molecular Testing Market
The global onco-hematology molecular testing market is evolving rapidly due to innovations in technology, growing healthcare demands, and improvements in diagnostic techniques. Countries like the United States, China, Germany, India, and Japan are key players, contributing significantly to advancements in cancer and blood disorder testing. This market's developments reflect efforts to enhance early detection, personalized treatment options, and patient outcomes across diverse global healthcare landscapes.
United States: The U.S. is at the forefront of onco-hematology molecular testing, driven by significant investments in precision medicine. The country is witnessing increased adoption of next-generation sequencing (NGS) and liquid biopsy technologies. The FDA's approval of several molecular diagnostic tools for hematologic cancers has catalyzed the growth of this market. Moreover, collaboration between biotech companies and healthcare providers is accelerating the development of personalized treatment strategies for patients with leukemia, lymphoma, and other blood cancers.
China: China's onco-hematology molecular testing market is experiencing rapid growth due to increasing healthcare access and technological advancements. The government's emphasis on enhancing its healthcare infrastructure and funding cancer research is contributing to the adoption of molecular diagnostics. Chinese companies are also focusing on the development of affordable testing solutions, while collaborations with global players are helping to introduce cutting-edge technologies like NGS and gene editing tools to diagnose hematological malignancies more effectively.
Germany: Germany is a leader in Europe for onco-hematology molecular testing, supported by a strong healthcare system and robust R&D efforts. With a high level of adoption of advanced technologies like NGS and PCR-based tests, Germany is making strides in the molecular profiling of hematologic cancers. Moreover, German healthcare institutions are prioritizing the development of minimally invasive diagnostic methods, such as liquid biopsies, to detect genetic mutations and alterations in blood disorders early on.
India: India's onco-hematology molecular testing market is expanding as the healthcare sector modernizes. Key drivers include improved healthcare access, greater awareness of cancer and blood disorders, and an increase in affordable diagnostic options. India is also experiencing a rise in public and private collaborations focused on introducing molecular diagnostic tools for hematologic cancers. With the growing burden of cancer in the country, advancements in testing technology and genetic profiling are enhancing personalized treatment approaches.
Japan: Japan's onco-hematology molecular testing market benefits from strong government support and advanced technology. Japan is known for its robust healthcare infrastructure, allowing for the swift integration of molecular diagnostics into clinical practice. The country's focus on precision medicine is driving innovations in diagnostic technologies, such as liquid biopsies and targeted sequencing, enabling the identification of genetic mutations and optimizing treatment strategies for hematologic malignancies like leukemia and lymphoma.
Features of the Global Onco-Hematology Molecular Testing Market
Market Size Estimates: Onco-hematology molecular testing market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Onco-hematology molecular testing market size by type, application, and region in terms of value ($B).
Regional Analysis: Onco-hematology molecular testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the onco-hematology molecular testing market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the onco-hematology molecular testing market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the onco-hematology molecular testing market by type (qPCR, dPCR, next-generation sequencing, and others), application (national reference lab / specialty lab, university hospital, and community hospital), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Table of Contents
1. Executive Summary
2. Market Overview
2.1 Background and Classifications
2.2 Supply Chain
3. Market Trends & Forecast Analysis
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment
4. Global Onco-Hematology Molecular Testing Market by Type
4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 qPCR: Trends and Forecast (2019-2031)
4.4 dPCR: Trends and Forecast (2019-2031)
4.5 Next-Generation Sequencing: Trends and Forecast (2019-2031)
4.6 Others: Trends and Forecast (2019-2031)
5. Global Onco-Hematology Molecular Testing Market by Application
5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 National Reference Lab / Specialty Lab: Trends and Forecast (2019-2031)
5.4 University Hospital: Trends and Forecast (2019-2031)
5.5 Community Hospital: Trends and Forecast (2019-2031)
6. Regional Analysis
6.1 Overview
6.2 Global Onco-Hematology Molecular Testing Market by Region
7. North American Onco-Hematology Molecular Testing Market
7.1 Overview
7.2 North American Onco-Hematology Molecular Testing Market by type
7.3 North American Onco-Hematology Molecular Testing Market by application
7.4 United States Onco-Hematology Molecular Testing Market
